61MO Phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828) in advanced solid tumours: Overall safety, and efficacy in patients (pts) with well-differentiated liposarcoma (WDLPS)
Reichardt P, Schöffski P, Lorusso P, Yamamoto N, Garcia V, Lugowska I, Lauer U, Somaiah N, Hu C, Landsteiner H, Jayadeva G, Gounder M. 61MO Phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828) in advanced solid tumours: Overall safety, and efficacy in patients (pts) with well-differentiated liposarcoma (WDLPS). ESMO Open 2024, 9: 102451. DOI: 10.1016/j.esmoop.2024.102451.Peer-Reviewed Original Research